🇺🇸 FDA
Patent

US 11883492

Combination treatment of chemoresistant cancers

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11883492 (Combination treatment of chemoresistant cancers) held by The Regents of the University of California expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/337